What can the Pharmakogenetik Medicheck tell you — and what not?

The MyBody-X Pharmakogenetik Medicheck analyzes selected genetic variants that can influence drug metabolism, such as CYP enzymes (e.g., CYP2D6, CYP2C19). It may indicate whether you metabolize certain drugs (e.g., antidepressants, proton pump inhibitors) faster or slower, which can aid in dosing decisions. However, it does **not** cover all relevant pharmacogenes (e.g., HLA markers for severe adverse reactions, UGT1A1 for irinotecan). Results are predictive, not diagnostic – most drug responses involve multiple genes and lifestyle factors. Clinical validation for many tested SNPs is limited. The test is not a substitute for professional pharmacogenetic counseling or comprehensive clinical testing. Evidence is mixed: some associations are well-studied, but many claims rely on marketing. Caveat: without medical interpretation, results may lead to incorrect dosing or unnecessary worry.